Elanco offers anti-parasitic drug divestment to allay Australian concerns over Bayer deal
US-based Elanco Animal Health has proposed to divest some of its animal-health products, in a bid to clear an informal Australian review of its plans to acquire the animal-health business of...To view the full article, register now.
Already a subscriber? Click here to view full article